New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
1,355.42
3.77
+0.28%
Follow LLY
Alert me
Revenue to profit Fiscal 2025, year to Dec 31, 2025
Of every $100 of revenue, $31.67 was left as profit. Gross margin has risen four years running, from 74.2% to 83.0%. What is an income statement?
| Revenue | 65.2 | 100.0% |
|---|---|---|
| Cost of revenue | −11.1 | −17.0% |
| Gross profit | 54.1 | 83.0% |
| Research & development | −13.3 | −20.5% |
| Selling, general & admin | −11.1 | −17.0% |
| Other operating costs | −3.4 | −5.2% |
| Operating income | 26.3 | 40.4% |
| Other income, net | −0.6 | −0.9% |
| Income tax | −5.1 | −7.8% |
| Net income | 20.6 | 31.7% |
Net margin (right axis)
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.2B | $20.0B | $21.5B | $22.3B | $24.5B | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Operating income | $3.3B | $2.0B | $3.5B | $5.0B | $6.1B | $6.4B | $7.1B | $6.5B | $12.9B | $26.3B |
| Net income | $2.7B | −$204M | $3.2B | $8.3B | $6.2B | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| Net margin (right axis) | 12.9% | −1.0% | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
65,179.00 | 45,043.00 | 34,124.00 | 28,541.40 | 28,318.40 | 24,539.80 | 22,319.50 | 21,493.30 | 19,973.80 | 21,222.10 |
Revenue Growth |
44.70% | 32.00% | 19.56% | 0.79% | 15.40% | 9.95% | 3.84% | 7.61% | (5.88%) | 6.33% |
Cost of Revenue |
11,052.00 | 8,418.00 | 7,082.00 | 6,629.80 | 7,312.80 | 5,483.30 | 4,721.20 | 4,681.70 | 4,447.70 | 5,710.10 |
Gross Profit |
54,127.00 | 36,625.00 | 27,042.00 | 21,911.60 | 21,005.60 | 19,056.50 | 17,598.30 | 16,811.60 | 15,526.10 | 15,512.00 |
R&D Expenses |
13,337.00 | 10,991.00 | 9,313.00 | 7,190.80 | 6,930.70 | 5,976.30 | 5,595.00 | 5,051.20 | 5,096.20 | 5,310.30 |
SG&A Expenses |
11,094.00 | 8,594.00 | 7,404.00 | 6,440.40 | 6,431.60 | 6,121.20 | 6,213.80 | 5,975.10 | 5,982.40 | 6,528.00 |
Operating Income |
26,302.00 | 12,899.00 | 6,457.00 | 7,127.30 | 6,357.10 | 6,058.00 | 4,974.30 | 3,534.50 | 2,003.30 | 3,261.20 |
Non-operating Income/Expense |
(571.00) | (219.00) | 97.00 | (320.90) | (201.60) | 1,171.90 | 291.60 | 145.60 | 301.50 | 112.80 |
| 25,731.00 | 12,680.00 | 6,554.00 | 6,806.40 | 6,155.50 | 7,229.90 | 5,265.90 | 3,680.10 | 2,304.80 | 3,374.00 | |
Income Tax Provision |
5,091.00 | 2,090.00 | 1,314.00 | 561.60 | 573.80 | 1,036.20 | 628.00 | 529.50 | 2,391.20 | 636.40 |
Income after Tax |
20,640.00 | 10,590.00 | 5,240.00 | 6,244.80 | 5,581.70 | 6,193.70 | 4,637.90 | 3,150.60 | (86.40) | 2,737.60 |
Net Income Common |
20,640.00 | 10,590.00 | 5,240.00 | 6,244.80 | 5,581.70 | 6,193.70 | 8,318.40 | 3,232.00 | (204.10) | 2,737.60 |
EPS (Basic) |
22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | (0.19) | 2.58 |
EPS (Diluted) |
22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | (0.19) | 2.58 |
Shares (Basic, Weighted) |
897.30 | 900.60 | 900.20 | 901.74 | 906.96 | 907.63 | 931.06 | 1,027.72 | 1,052.02 | 1,058.32 |
Shares (Diluted, Weighted) |
899.30 | 904.10 | 903.30 | 904.62 | 911.68 | 912.51 | 935.68 | 1,033.67 | 1,052.02 | 1,061.83 |
Gross Margin |
83.04% | 81.31% | 79.25% | 76.77% | 74.18% | 77.66% | 78.85% | 78.22% | 77.73% | 73.09% |
EBIT Margin |
40.35% | 28.64% | 18.92% | 24.97% | 22.45% | 24.69% | 22.29% | 16.44% | 10.03% | 15.37% |
EBT margin |
39.48% | 28.15% | 19.21% | 23.85% | 21.74% | 29.46% | 23.59% | 17.12% | 11.54% | 15.90% |
Net Profit Margin |
31.67% | 23.51% | 15.36% | 21.88% | 19.71% | 25.24% | 37.27% | 15.04% | (1.02%) | 12.90% |
Free Cash Flow Margin |
13.77% | 8.35% | 2.32% | 20.08% | 21.39% | 20.83% | 17.04% | 20.07% | 22.72% | 18.32% |
EBITDA |
28,299.00 | 14,666.00 | 7,984.00 | 8,649.80 | 7,904.70 | 7,381.90 | 6,206.90 | 5,143.50 | 3,570.60 | 4,757.80 |
EBIT |
26,302.00 | 12,899.00 | 6,457.00 | 7,127.30 | 6,357.10 | 6,058.00 | 4,974.30 | 3,534.50 | 2,003.30 | 3,261.20 |
Income from Continuous Operations |
20,640.00 | 10,590.00 | 5,240.00 | 6,244.80 | 5,581.70 | 6,193.70 | 4,637.90 | 3,150.60 | (86.40) | 2,737.60 |
Income from Discontinued Operations |
— | — | — | — | — | — | 3,680.50 | 81.40 | (117.70) | — |
Consolidated Net Income/Loss |
20,640.00 | 10,590.00 | 5,240.00 | 6,244.80 | 5,581.70 | 6,193.70 | 8,318.40 | 3,232.00 | (204.10) | 2,737.60 |
EPS (Basic, from Continuous Ops) |
23.00 | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 | 4.98 | 3.07 | (0.08) | 2.59 |
EPS (Basic, from Discontinued Ops) |
— | — | — | — | — | — | 3.95 | 0.07 | (0.11) | — |
EPS (Basic, Consolidated) |
23.00 | 11.76 | 5.82 | 6.93 | 6.15 | 6.82 | 8.93 | 3.14 | (0.19) | 2.59 |
EPS (Diluted, from Cont. Ops) |
22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 | 3.05 | (0.08) | 2.58 |
EPS (Diluted, from Disc. Ops) |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — |
Shares (Diluted, Average) |
899.30 | 904.06 | 903.28 | 904.62 | 911.68 | 912.51 | 935.68 | 1,033.67 | 1,052.02 | 1,061.83 |
EPS (Diluted, Consolidated) |
22.95 | 11.71 | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 | 3.13 | (0.19) | 2.58 |
EBITDA Margin |
43.42% | 32.56% | 23.40% | 30.31% | 27.91% | 30.08% | 27.81% | 23.93% | 17.88% | 22.42% |
Operating Cash Flow Margin |
25.80% | 19.58% | 12.43% | 26.58% | 26.01% | 26.49% | 21.67% | 25.70% | 28.11% | 22.86% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026